MedTrace Logo

Study Evaluating Refacto For Pharmacovigilance

NCT00195442 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 288

Last updated 2011-02-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.

Conditions

Interventions

DRUG

Moroctocog alfa

Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00195442 on ClinicalTrials.gov